Key Insiders Commit 15.4% Stake to Back Eli Lilly's $6.75/Share Buyout

summarizeSummary

AtaiBeckley's largest shareholders, Apeiron and Christian Angermayer, have agreed to vote their 15.4% stake in favor of Eli Lilly's $6.75/share acquisition, significantly de-risking the deal's approval.

check_boxKey Events · M&A and Partnerships · ATAI

• Insiders Lock Up 15.4% Stake

  Apeiron Investment Group and Christian Angermayer entered Voting and Support Agreements with Eli Lilly, committing to vote their combined 56.8 million shares (15.4% of outstanding) in favor of the merger.

• Merger Terms Confirmed

  The filing reiterates the acquisition price of $6.75 per share in cash plus up to $2.50 per share in contingent value rights, as announced on July 16, 2026.

• Transfer Restrictions Imposed

  The Support Agreements prohibit Apeiron and Angermayer from transferring their shares, preventing large insider sales that could pressure the stock before the shareholder vote.

• Deal Approval De-Risked

  With 15.4% of shares already committed in favor, the merger faces a lower hurdle for shareholder approval, increasing the probability of closing.

auto_awesomeAnalysis · ATAI · Life Sciences

Apeiron Investment Group and Christian Angermayer, who together control 15.4% of AtaiBeckley, have signed Voting and Support Agreements pledging to vote for the Eli Lilly acquisition. This locks in a significant block of shares in favor of the deal, reducing the risk of a shareholder revolt and increasing the likelihood of the merger closing. The agreements also restrict share transfers, preventing these insiders from selling into the market and potentially destabilizing the stock ahead of the vote. The filing confirms the merger price of $6.75 per share in cash plus up to $2.50 in CVRs, aligning with yesterday's announcement.